| 1 |
郑荣寿，陈 茹，韩冰峰，等.2022 年中国恶性肿瘤流行情况分析［J］.中华肿瘤杂志，2024，46（3）：221-231.
|
| 2 |
吴国明，钱桂生.非小细胞肺癌靶向治疗研究进展及新理念［J/CD］.中华肺部疾病杂志（电子版），2019，12（4）：405-408.
|
| 3 |
孟芸畅，许 可，宋 勇.新辅助免疫治疗在可切除非小细胞肺癌中的研究进展［J/CD］.中华肺部疾病杂志（电子版），2023，16（5）：734-738.
|
| 4 |
Sathish G，Monavarshini LK，Sundaram K，et al.Immunotherapy for lung cancer［J］.Pathol Res Pract，2024，254：155104.
|
| 5 |
Lahiri A，Maji A，Potdar PD，et al.Lung cancer immunotherapy：progress，pitfalls，and promises［J］.Mol Cancer，2023，22（1）：40.
|
| 6 |
Swart M，Verbrugge I，Beltman JB.Combination approaches with immune-checkpoint blockade in cancer therapy［J］.Front Oncol，2016，6：233.
|
| 7 |
Sharma P，Allison JP.The future of immune checkpoint therapy［J］.Science，2015，348（6230）：56-61.
|
| 8 |
Chen DS，Mellman I.Elements of cancer immunity and the cancerimmune set point［J］.Nature，2017，541（7637）：321-330.
|
| 9 |
Dostert C，Grusdat M，Letellier E，et al.The TNF family of ligands and receptors：Communication modules in the immune system and beyond［J］.Physiol Rev，2019，99（1）：115-160.
|
| 10 |
Lu X.OX40 and OX40L interaction in Cancer［J］.Curr Med Chem，2021，28（28）：5659-5673.
|
| 11 |
Buchan SL，Rogel A，Al-Shamkhani A.The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy［J］.Blood，2018，131（1）：39-48.
|
| 12 |
Thapa B，Kato S，Nishizaki D，et al.OX40/OX40 ligand and its role in precision immune oncology［J］.Cancer Metastasis Rev，2024，43（3）：1001-1013.
|
| 13 |
Xu Y，Yu Q.E-cadherin negatively regulates CD44-hyaluronan interaction and CD44-mediated tumor invasion and branching morphogenesis［J］.J Biol Chem，2003，278（10）：8661-8668.
|
| 14 |
Diab A，Hamid O，Thompson JA，et al.A phase I，open-label，dose-escalation study of the OX40 agonist ivuxolimab in patients with locally advanced or metastatic cancers［J］.Clin Cancer Res，2022，28（1）：71-83.
|
| 15 |
Davis EJ，Martin-Liberal J，Kristeleit R，et al.First-in-human phaseⅠ/Ⅱ，open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors［J］.J Immunother Cancer，2022，10（10）：e004235.
|
| 16 |
Kuang Z，Jing H，Wu Z，et al.Development and characterization of a novel anti-OX40 antibody for potent immune activation［J］.Cancer Immunol Immunother，2020，69（6）：939-950.
|
| 17 |
Buchan SL，Rogel A，Alshamkhani A.The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy［J］.Blood，2017，131（1）：39-48.
|
| 18 |
Aspeslagh S，Postel-Vinay S，Rusakiewicz S，et al.Rationale for anti-OX40 cancer immunotherapy［J］.Eur J Cancer，2016，52：50-66.
|
| 19 |
Webb GJ，Hirschfield GM，Lane PJ.OX40，OX40L and autoimmunity：A comprehensive review［J］.Clin Rev Allergy Immunol，2016，50（3）：312-332.
|
| 20 |
Lin Y，Song Y，Zhang Y，et al.NFAT signaling dysregulation in cancer：Emerging roles in cancer stem cells ［ J］.Biomed Pharmacother，2023，165：115167.
|
| 21 |
Lv YW，Chen Y，Lv HT，et al.Kawasaki disease OX40-OX40L axis acts as an upstream regulator of NFAT signaling pathway［J］.Pediatr Res，2019，85（6）：835-840.
|
| 22 |
Zhou Z，Lin L，An Y，et al.The combination immunotherapy of TLR9 agonist and OX40 agonist via intratumoural injection for hepatocellular carcinoma［J］.J Hepatocell Carcinoma，2021，8：529-543.
|
| 23 |
Iriki H，Takahashi H，Amagai M.Diverse role of OX40 on T cells as a therapeutic target for skin diseases［J］.J Invest Dermatol，2023，143（4）：545-553.
|
| 24 |
Yan LH，Liu XL，Mo SS，et al.OX40 as a novel target for the reversal of immune escape in colorectal cancer［J］.Am J Transl Res，2021，13（3）：923-934.
|
| 25 |
Alvim RG，Georgala P，Nogueira L，et al.Combined OX40 agonist and PD-1 inhibitor immunotherapy improves the efficacy of vascular targeted photodynamic therapy in a urothelial tumor model［J］.Molecules，2021，26（12）：3744.
|
| 26 |
Ruby CE，Yates MA，Hirschhorn-Cymerman D，et al.Cutting Edge：OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right［J］.J Immunol，2009，183（8）：4853-4857.
|
| 27 |
Imianowski CJ ，Kuo P，Whiteside SK，et al.IFNγ production by functionally reprogrammed tregs promotes antitumor efficacy of OX40/CD137 bispecific agonist therapy［J］.Cancer Res Commun，2024，4（8）：2045-2057.
|
| 28 |
Kitamura N，Murata S，Ueki T，et al.OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity［J］.Int J Cancer，2009，125（3）：630-638.
|
| 29 |
Weinberg AD，Morris NP，Kovacsovics-Bankowski M，et al.Science gone translational：the OX40 agonist story［J］.Immunol Rev，2011，244（1）：218-231.
|
| 30 |
Polesso F，Sarker M，Weinberg AD，et al.OX40 agonist tumor immunotherapy does not impact regulatory T cell suppressive function［J］.J Immunol，2019，203（7）：2011-2019.
|
| 31 |
Curti BD，Kovacsovics-Bankowski M，Morris N，et al.OX40 is a potent immune-stimulating target in late-stage cancer patients［J］.Cancer Res，2013，73（24）：7189-7198.
|
| 32 |
Jensen SM，Maston LD，Gough MJ，et al.Signaling through OX40 enhances antitumor immunity［J］.Semin Oncol，2010，37（5）：524-532.
|
| 33 |
Nuebling T，Schumacher CE，Hofmann M，et al.The immune checkpoint modulator OX40 and its ligand OX40L in NK-cell immunosurveillance and acute myeloid leukemia ［ J］.Cancer Immunol Res，2018，6（2）：209-221.
|
| 34 |
Shibahara I，Saito R，Zhang R，et al.OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment：A clue for successful immunotherapy［J］.Mol Cancer，2015，14：41.
|
| 35 |
Weinberg AD，Morris NP，Kovacsovics-Bankowski M，et al.Science gone translational：the OX40 agonist story［J］.Immunol Rev，2011，244（1）：218-231.
|